OncoSec Medical Incorporated (ONCSQ)

Market Cap	6.00 -100.0%
Revenue (ttm)	n/a
Net Income	-29.39M
EPS	-14.77
Shares Out	5.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,012
Average Volume	25,334
Open	0.0000
Previous Close	n/a
Day's Range	0.0000 - 0.0000
52-Week Range	0.0000 - 0.0001
Beta	9.96
RSI	58.54
Earnings Date	n/a

About OncoSec Medical

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company’s product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 41
• Stock Exchange: OTCMKTS
• Ticker Symbol: ONCSQ